Losartan Potassium + Hydrochlorothiazide

Low folate status contributes to elevated homocysteine, a metabolite that has been associated with endothelial dysfunction, arterial stiffness, and a higher risk of stroke and coronary heart disease. Large observational studies consistently show that individuals with higher homocysteine levels have greater rates of cardiovascular events, and folate intake is one of the key nutritional determinants of homocysteine. Clinically, folic acid supplementation (often combined with vitamins B6 and B12) can lower homocysteine and appears to modestly reduce stroke risk in some populations, making the identification and correction of folate deficiency an important part of broader cardiovascular risk reduction.

Low or depleted magnesium levels are associated with a higher likelihood of several cardiovascular problems, including arrhythmias, where people with low magnesium have been shown to have 2–4 times higher odds of these rhythm disturbances compared with those with normal levels. Low magnesium is also linked to worsening coronary artery disease, progression of heart failure, and development or aggravation of hypertension, driven by disrupted cardiac electrical stability, vascular function, and electrolyte balance. Even mild magnesium depletion may contribute to higher blood pressure over time, adding to the overall cardiovascular burden, especially in individuals with existing heart disease or multiple risk factors.

Folate deficiency in the periconceptional period significantly increases the risk of neural tube defects (NTDs) such as spina bifida and anencephaly, because adequate folate is required for proper closure of the embryonic neural tube in the first month of pregnancy. Large observational datasets and randomized trials have shown that appropriate folic acid supplementation before conception and in early pregnancy can reduce NTD risk by roughly 50–70% in the general population, with even greater risk reduction in women with a prior NTD‑affected pregnancy. The practical implication is that all women of childbearing potential, not just those actively planning pregnancy, are typically advised to maintain adequate daily folic acid intake so that red‑cell folate stores are sufficient well before conception occurs.

CoQ10 deficiency can present in infancy as a severe encephalomyopathy or multisystemic mitochondrial disease, with features such as hypotonia, developmental delay, intractable seizures, lactic acidosis, cardiomyopathy, and failure to thrive. Reports of infantile‑onset multisystem CoQ10 deficiency describe very early presentations, sometimes in the neonatal period, with rapid neurologic deterioration and involvement of brain, heart, kidney, and liver, and many affected children die in the first months or years of life despite intensive care. The important clinical point is that, although outcomes are often poor in the most severe cases, some infants and young children show neurologic improvement or stabilization when CoQ10 deficiency is recognized early and high‑dose CoQ10 supplementation is started promptly, which is why this diagnosis is considered a treatable cause of infantile encephalomyopathy

CoQ10 is a key mitochondrial antioxidant, and circulating levels are often reduced in people with chronic kidney disease and chronic heart failure, where deficiency is linked to greater oxidative stress and poorer organ function. In CKD cohorts, lower CoQ10 levels correlate with increased cardiovascular risk, and supplementation has been reported to improve markers such as proteinuria, mitochondrial function, and oxidative stress, with some studies suggesting better preservation of kidney function over time. In patients with chronic heart failure, trials such as Q-SYMBIO have shown that CoQ10 supplementation can improve cardiac function parameters and significantly reduce major adverse cardiovascular events, cardiovascular mortality, and heart‑failure–related hospitalizations.

Potassium deficiency can destabilize the heart’s electrical system, so hypokalemia is a well‑known trigger for cardiac arrhythmias and can present with palpitations, “skipped beats,” or more dangerous rhythm disturbances even before other symptoms are obvious. As serum potassium drops, characteristic ECG changes (flattened or inverted T waves, ST‑segment depression, prominent U waves, and QT‑interval prolongation) reflect impaired repolarization, which can progress to premature ventricular contractions, atrial fibrillation, ventricular tachycardia, torsade de pointes, or even ventricular fibrillation and cardiac arrest in severe cases. Observational data show that hypokalemia and even low‑normal potassium levels increase the risk of ventricular arrhythmias and sudden cardiac death in people with underlying heart disease, highlighting the importance of monitoring and promptly correcting potassium deficits in hospitalized and high‑risk patients.